Zamani Rarani, Fahimeh
Zamani Rarani, Mohammad
Hamblin, Michael R.
Rashidi, Bahman
Hashemian, Seyed Mohammad Reza
Mirzaei, Hamed
Article History
Received: 14 March 2022
Accepted: 6 July 2022
First Online: 30 July 2022
Declarations
:
: Not applicable.
: Not applicable.
: M.R.H. declares the following potential conflicts of interest. Scientific Advisory Boards: Transdermal Cap Inc., Cleveland, OH; Hologenix Inc. Santa Monica, CA; Vielight, Toronto, Canada; JOOVV Inc., Minneapolis-St. Paul MN; Consulting; USHIO Corp, Japan; Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, Germany. Stockholding: Niraxx Light Therapeutics, Inc., Irvine CA; JelikaLite Corp., New York NY. The other authors declare no conflicts of interest.